GlobeNewswire
-
Drop Off Toys 24/7 at 4 Ally Medical ER Locations for Austin Toy Drive
20/11/2026 -
NMDP appoints new board chair and welcomes new directors
20/11/2026 -
PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
20/11/2026 -
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/11/2026 -
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
20/11/2026 -
For Smaller Travel Operators, Outsourcing Reservation Support Starts With Who Can Change a Booking
20/11/2026 -
Quanta Presents Class-Leading Monotherapy Data for QTX3034 in KRAS G12D-Mutant Advanced Endometrial Cancer at the EORTC-NCI-AACR Symposium
20/11/2026 -
DXS International Plc (AQSE: DXSP): Result of DXS AGM 2026
20/11/2026 -
Leads Biolabs Presents Opamtistomig (PD-L1/4-1BB Bispecific Antibody) to Global Investors at the 2026 Jefferies Global Healthcare Conference
20/11/2026 -
IBA vend un premier système à rayons X Rhodotron® LITE dans la foulée de son lancement
20/11/2026 -
First Rhodotron® LITE X-ray system sold shortly after launch
20/11/2026 -
ADDEX THERAPEUTICS TO REPORT 2026 THIRD QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 25, 2026
20/11/2026 -
MGMA Names Chris DeRienzo, MD, MPP, as Next Chief Executive Officer
19/11/2026 -
Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
20/11/2026 -
Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award
20/11/2026 -
Spryte Medical Announces Positive Results from the INSYTE Pivotal Trial at SVIN 2026
19/11/2026 -
Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026
19/11/2026 -
Sevaro Health Unveils New Brand as It Grows Beyond Neurology to Expand Access to Tech-Enabled Specialty Care
19/11/2026 -
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
19/11/2026
Pages